Still racing to achieve MDR compliance? A transition period update

Sandra Gopinath
Racing to achieve MDR compliance

At the EPSCO Board meeting on December 9, 2022, the EU Health Minister urged the European Commission to extend the transition period for the Medical Device Regulation. The proposal was under consideration of the European Parliament and the Council.

On January 6th 2023, the EU commission has adopted the proposal to extend the transition rules of Medical Device Regulation (EU) 2017/745 (MDR) to allow more time for certification and to alleviate the foreseeable shortage of medical devices.

Status quo

Under transitional arrangements, medical devices are allowed to enter the EU market under CE certifications issued according to Directive 93/42/EEC (MDD) or 90/385/EEC (AIMDD). The previously extended MDR transition time was due to end on 26 May 2024, meaning that after this time devices would require a recertification under MDR.

Numerous industry stakeholders and key opinion leaders had expressed concerns in recent months that this deadline is unrealistic and that its implementation could have an impact on the continuous availability of different medical devices required by patients and healthcare providers in the EU.

Moreover, opinions were that the suggested transitional time range could jeopardise research and innovation in addition to availability issues by delaying access to cutting-edge medical devices in EU nations.

In addition to the strong backlash from stakeholders, limitations in Notified Body capacity was also a significant factor in calls for an extension to the transition period.

The proposal

In order to address the concerns and mitigate foreseeable risks associated with device shortage, the EU commission proposed a longer transition period with new deadlines depending on the medical device’s risk class.

It is worth noting that the proposal does not alter any of the existing performance and safety standards outlined in the Medical Device Regulation 2017/745. It only amends the transitional provisions to provide additional time to transfer from the formerly applicable norms.

Key elements of the proposal:

The transition periods for medical devices authorised under Directive 93/42/EEC (Medical Device Directive) will now last until 31 December 2027 for high risk (Class III and IIb) devices, until 31 December 2028 for medium and low risk (Class IIa and I) devices and until 26 May 2026 for class III implantable custom-made devices.

It is important to note that these extensions are subject to certain conditions. They are only applicable to devices:

  1. that are “safe”, that do not pose an unacceptable risk to health & safety
  2. which have not undergone any significant changes in its intended purpose or design
  3. those for which manufacturers have already taken steps to transition to the rules provided by MDR

In case of custom-made devices, the transition period is also subject to the application of the manufacturer for a conformity assessment of the device before 26 May 2024.

Elimination of the "sell-off" date of 26 May 2025 that is currently established in the Medical Device Regulation. The "sell-off" date designates the time after which products that have already been sold and are still on the market should be withdrawn.

Removing the “sell-off” date will, it is argued, prevent safe medical devices from being removed from the market.

What this means

While it will be warmly welcomed by many, the proposal to delay the transitional period now has to be approved by the European Parliament and the Council through an expedited co-decision process. For this reason, manufacturers are still encouraged to continue working towards compliance with the MDR as soon as possible, as the extension is not a “free pass”.

Notified Bodies will be still monitoring and auditing compliance during the extension period, and as outlined above, the transition period only applies to devices “for which manufacturers have already taken steps to transition to the rules provided by MDR.” Additionally, for Class III devices, the transition period is subject to the application of the manufacturer for a conformity assessment before 26 May 2024.

So, whether approved by the European Parliament and Council or not, it’s not time to forget about MDR certification. It may, however, take off some of the pressure.

Please contact us if you have any questions about this article or would like to discuss our products and services in more detail.

Related articles

  1. A pile of question marks

    Mantra Systems at MEDICA 2023

    Mantra Systems is going to MEDICA 2023, the largest medical trade fair in the world. We hope to see you there.

    Shen May Khoo Shen May Khoo Junior Regulatory Specialist
  2. A pile of question marks

    Medical Device 'Significant Changes' – Navigating EU MDR Article 120(3) using MDCG 2020-3 rev. 1

    Understand what changes to your medical device are considered 'significant' under EU MDR (2017/745).

    Shen May Khoo Shen May Khoo Junior Regulatory Specialist
  3. A signpost giving unsure directions

    MDR or IVDR - A sibling rivalry?

    A guide to easily understanding whether your device is a medical device or an in vitro diagnostic medical device (IVD).

    Dr Gayle Buchel Dr Gayle Buchel Lead Medical Writer
  4. An EU and UK flag

    What the latest Brexit U-turn means for CE Marking of medical devices in Great Britain

    Will Great Britain continue to allow the use of the CE mark for medical devices beyond the 2024 deadline?

    Dr Hanna Gul Dr Hanna Gul Lead Medical Writer
  5. A woman writing her own medical device regulation documentation

    Gain confidence, reassurance and control over your EU MDR strategy

    Find out how to build your own technical files within a guided framework while minimising financial outlays.

    Dr Gayle Buchel Dr Gayle Buchel Lead Medical Writer
  6. A 7-step guide to navigating regulatory requirements for medical device start-ups

    A medical device regulations guide for start-up companies

    We present a 7-step guide to navigating regulatory requirements on a budget.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  7. An update on UKCA Marking of Medical Devices

    UKCA Marking of Medical Devices – An update on the status quo

    We review recently updated requirements for UKCA marking and what it means for your regulatory strategy.

    Dr Hanna Gul Dr Hanna Gul Lead Medical Writer
  8. How to choose a CER writer for your MDR Clinical Evaluation

    Choosing a CER writer for your MDR Clinical Evaluations

    We've compiled a list of considerations that will help you make the right choice when choosing a CER writer.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  9. Achieving MDR Compliance for Class I medical devices

    How to achieve MDR Compliance for Class I medical devices

    We outline a strategy for the regulatory compliance of Class I medical devices.

    Sandra Gopinath Sandra Gopinath Senior Regulatory Specialist
  10. Literature Search Protocols & SOTA Reviews for medical devices and what to know before you start

    Literature searches and reviews for medical devices - what to know before you start

    We explain what you should know before beginning a literature search & review for your medical device.

    Sandra Gopinath Sandra Gopinath Senior Regulatory Specialist
  11. How PMCF goes beyond simple compliance - improving products and engaging customers

    How PMCF goes beyond simple compliance

    The wider benefits of a well-designed PMCF system include improving your products and your relationship with your clients.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  12. MDR Compliance Webinar - A masterclass on building a winning EU MDR strategy for your medical devices

    Build a winning EU MDR strategy for your medical devices

    Watch our CEO, Dr Paul Hercock, deliver a Mantra Systems webinar on MDR compliance strategy.

    Richard Jones Richard Jones Systems Manager
  13. Ensure medical device regulatory compliance of your devices through Brexit

    The impact of Brexit on medical device regulatory compliance

    How to ensure regulatory alignment of your devices in the territories affected by Brexit.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  14. Use medical device regulatory consulting services to supercharge your MDR transition

    Is outside consulting support the answer to your MDR transition?

    Getting ready for the MDR is a demanding process. Outsourcing might be your solution.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  15. Simplifying the challenges posed by the new EU MDR

    Simplifying the challenges posed by the new EU MDR

    Our CEO Dr Paul Hercock was invited to speak on a Kaizen Life Sciences podcast about the challenges posed by the EU MDR.

    Dr Victoria Cartwright Dr Victoria Cartwright Relationship Manager
  16. Software as a Medical Device

    Software as a Medical Device

    Unless you have spent time working with medical device legislation in the past, the idea that software could be a medical device may be rather unexpected.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  17. Coronavirus and medical device regulations

    Relaxing medical device regulatory requirements during a healthcare crisis

    During the coronavirus pandemic, how far should we go when relaxing medical device regulatory requirements?

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  18. EU flag

    A proposal to delay the EU MDR gets approved

    A vote in the European Parliament has decisively approved a delay to full implementation of the EU MDR by one year.

    Richard Jones Richard Jones Systems Manager
  19. EU regulators may delay MDR enforcement

    EU regulators may delay MDR enforcement. Out of the woods?

    A delay of the MDR would be welcome news for many, but what would a delay mean in practice? To what extent can preparations for EU MDR be put on ice?

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  20. The new MDR compliance challenge

    The new MDR compliance challenge

    Across the industry, medical device companies are facing challenges in meeting the demands of the new Medical Device Regulations (MDR) 2017/745 framework.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer

More articles

Do you need help with your regulatory strategy?

Talk to us